ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseaseNicoletta Colombo, Siel Olbrecht, François Planchamp et al.|Annals of Oncology|2019Cited by 1.2k
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R. Clamp, Jonathan A. Ledermann, Elizabeth C James et al.|The Lancet|2019Cited by 223
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient dataPaul A. Cohen, Arjun Jeyarajah, Aime Powell et al.|Gynecologic Oncology|2019Cited by 121
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trialAndrew R. Clamp, Jonathan A. Ledermann, Elizabeth C James et al.|The Lancet Oncology|2022Cited by 45
OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancerEleni Frangou, Sarah P. Blagden, Gianfilippo Bertelli et al.|Gynecologic Oncology|2021Cited by 22